To access all features and enjoy the full functionality of this site, please ensure your browser is up-to-date. For IE8 users, the most recent version is IE11.

Our Johnson & Johnson family is focused on helping support the health of the general public

While the ways in which we work to improve the trajectory of eye health worldwide evolve, our vision remains steadfast: to help people see better, connect better, live better. 

Visit for the latest on how Johnson & Johnson is mobilizing its resources to help find solutions for COVID-19:

$50M Increase Investment for COVID-19

  • On March 27th, 2020, Johnson & Johnson announced a $50M increased investment for immediate COVID-19 response, primarily focused on supporting frontline health workers with.

COVID-19 Accelerated Vaccine Development

  • On March 30th, 2020 Johnson & Johnson announced the status of vaccine development and expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020, and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021. This is a substantially accelerated timeframe in comparison to the typical vaccine development process.

Questions? Reach out to your Sales Representative or Johnson & Johnson Customer Service at 1-800-874-5278.